Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JCEM.87.3.8355PMID 11889194
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.

  2009cited by this paper
• [Glucagon-like peptide-1(GLP-1)].

  2004cited by this paper
• Insulin Secretagogues

  2002cited by this paper
• Glucagon-like peptide-1.

  2001cited by this paper
• Studies of Interference in Serial Verbal Reactions

  2001cited by this paper
• Glucagon-like peptide-1: a potent regulator of food intake in humans

  1999cited by this paper
• Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia

  1998cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line.

  1998cited by this paper
• Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic β-Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling

  1998cited by this paper
• Normalization of fasting glycaemia by intravenous GLP‐1 ([7‐36 amide] or [7‐37]) in Type 2 diabetic patients

  1998influential reference
• Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1

  1998cited by this paper
• Effects of glucagon‐like peptide 1 (7–36 amide) on whole‐body protein metabolism in healthy man

  1997cited by this paper
• Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.

  1997cited by this paper
• Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

  1997cited by this paper
• Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors

  1997cited by this paper
• Glucagonlike peptide 1

  1997cited by this paper
• Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.

  1996cited by this paper
• Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

  1996cited by this paper
• Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I

  1996cited by this paper
• Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

  1996cited by this paper
• Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells.

  1996cited by this paper
• Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients

  1996cited by this paper
• No Effect of Beta‐adrenergic Blockade on Hypoglycaemic Effect of Glucagon‐like Peptide‐1 (GLP‐1) in Normal Subjects

  1996cited by this paper
• Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

  1995cited by this paper
• Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in Β TC3 cells and rat pancreatic beta cells

  1995cited by this paper
• Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7–36 amide] in the fasting state in healthy subjects

  1995influential reference
• Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

  1995cited by this paper
• How to measure insulin secretion.

  1994cited by this paper
• Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.

  1994cited by this paper
• Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

  1994cited by this paper
• Hypoglycemia

  1994cited by this paper
• Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable

  1993cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993influential reference
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993influential reference
• Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man

  1993cited by this paper
• Reversibility of unawareness of hypoglycemia in patients with insulinomas.

  1993cited by this paper
• Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

  1993cited by this paper
• Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance

  1992cited by this paper
• Gut hormones and diabetes mellitus.

  1992cited by this paper
• Evidence against important catecholamine compensation for absent glucagon counterregulation.

  1991cited by this paper
• Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction.

  1991influential reference
• Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting.

  1989cited by this paper
• Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide

  1989cited by this paper
• Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

  1988cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987influential reference
• Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2).

  1987cited by this paper
• Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut

  1987cited by this paper
• Dose—Response Relationships

  1987cited by this paper
• Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

  1986cited by this paper
• Comparison of Glucose Counterregulation During Short-Term and Prolonged Hypoglycemia in Normal Humans

  1986cited by this paper
• Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

  1985cited by this paper
• Effect of age on insulin stimulation of sympathetic nervous system activity in man.

  1982cited by this paper
• Hypoglycemia

  1980cited by this paper
• Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior.

  1980cited by this paper
• The incretin concept today

  1979cited by this paper
• Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range.

  1976cited by this paper

• Incretin-Based Therapies: A Novel Pathway in Addiction Treatment.

  2026cites this paper
• Glycemic variability and entero-pancreatic hormones signatures after different bariatric surgery procedures: a cross-sectional study

  2025cites this paper
• GLP-1 receptor agonism in cardiovascular disease prevention

  2025cites this paper
• Prevention of type 2 diabetes through prediabetes remission without weight loss

  2025cites this paper
• Effects of Glucagon-Like Peptide-1 Receptor Agonists After Treatment Withdrawal: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus

  2025cites this paper
• Rikkunshito prevents blood glucose intolerance in rats undergoing distal pancreatectomy

  2025cites this paper
• Incretin Hormone Levels (GLP‐1 and GIP) in Children and Adolescents With Type 1 Diabetes: A Systematic Review

  2025cites this paper
• Proglucagon-derived Peptides: Human Physiology and Therapeutic Potential.

  2025cites this paper
• Effects of Ramadan intermittent fasting on hormones regulating appetite in healthy individuals: A systematic review and meta-analysis.

  2025cites this paper
• Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Role of amylin in feeding and satiation.

  2025cites this paper
• Glucose-Dependent Effects of Exogenous Glucagon-Like Peptide-2 on Circulating Glucagon Levels in Healthy Men

  2025cites this paper
• Glucose-dependent insulinotropic polypeptide (GIP)

  2025cites this paper
• Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia - a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.

  2025cites this paper
• Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide

  2025cites this paper
• Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

  2024cites this paper
• Semaglutide and kidney function: friends or enemies?

  2024cites this paper
• Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery

  2024cites this paper
• Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism

  2024cites this paper
• GLP-1 RA for cardiometabolic risk reduction in obesity – How do we best describe benefit and value?

  2024cites this paper
• Physiological Appetite Regulation and Bariatric Surgery

  2024cites this paper
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review

  2024cites this paper
• Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials

  2024cites this paper
• Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity

  2024cites this paper
• Incretin therapy in feline diabetes mellitus - A review of the current state of research.

  2024cites this paper
• Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?

  2024cites this paper
• Glucagon-like peptide-1 and interleukin-6 interaction in response to physical exercise: An in-silico model in the framework of immunometabolism

  2024cites this paper
• Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs

  2024cites this paper
• A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity

  2024cites this paper
• Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment

  2024cites this paper
• GLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know

  2024cites this paper
• Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks

  2024cites this paper
• Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalation study

  2024cites this paper
• Symptomatology of hypoglycemia in diabetes: A bibliometric analysis (2000-2022) of bayesian approaches

  2024cites this paper
• Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes.

  2023cites this paper
• Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study

  2023cites this paper
• The protective role of GLP-1 in neuro-ophthalmology

  2023cites this paper
• Contribution of endogenous glucagon-like peptide 1 to prandial counterregulatory responses to hypoglycemia after bariatric surgery

  2023cites this paper
• Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity

  2023cites this paper
• A glucagon-like peptide-1 receptor antagonist reduces the insulin response to a glycemic meal in ponies

  2023cites this paper
• Bariatric surgery alters the postprandial recovery from hypoglycemia mediated by cholinergic signal.

  2023cites this paper
• Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy

  2023cites this paper
• In vivo mapping of hemodynamic responses mediated by tubuloglomerular feedback in hypertensive kidneys

  2023cites this paper
• GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid

  2023influential citation
• Biology and Clinical Use of Glucagon-Like-Peptide-1 Receptor Agonists in Vascular Protection.

  2023cites this paper
• Effect of Different Types of Hypoglycemic Medications on Psoriasis: An Analysis of Current Evidence

  2023cites this paper
• GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder

  2023cites this paper
• Medikamentöse Therapie der Adipositas – Konkurrenz zur bariatrischen Chirurgie oder sinnvolle Ergänzung?

  2023cites this paper
• Progress in the Study of the Role of Glucagon-Like Peptide 1 (GLP-1) in the Surgical Treatment of Obesity

  2023cites this paper
• First-phase insulin secretion: can its evaluation direct therapeutic approaches?

  2023cites this paper
• Ernährung bei fortgeschrittener Leberzirrhose und perioperativ bei Lebertransplantation

  2023influential citation
• Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs

  2023cites this paper
• 100 years of glucagon and 100 more

  2023cites this paper
• Incretin hormones and type 2 diabetes

  2023cites this paper
• Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller

  2023cites this paper
• The History of Obesity Research

  2022cites this paper
• Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence

  2022cites this paper
• The effects and side effects of liraglutide as a treatment for obesity

  2022cites this paper
• The molecular determinants of glucagon-like peptide secretion by the intestinal L-cell.

  2022cites this paper
• Gluclas: A software for computer-aided modulation of glucose infusion in glucose clamp experiments

  2022cites this paper
• Harnessing the Incretin System with Multi-Agonists

  2022cites this paper
• Type 2 diabetes and cardiovascular disease: risk reduction and early intervention

  2022cites this paper
• Reducing hyperglucagonaemia in type 2 diabetes using low‐dose glibenclamide: Results of the LEGEND‐A pilot study

  2022cites this paper
• Cardiovascular effects of incretins - focus on GLP-1 receptor agonists.

  2022cites this paper
• Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

  2022cites this paper
• Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?

  2022cites this paper
• Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis

  2022cites this paper
• GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.

  2022cites this paper
• Satiety Associated with Calorie Restriction and Time-restricted Feeding: Peripheral Hormones.

  2022cites this paper
• Quinine Effects on Gut and Pancreatic Hormones and Antropyloroduodenal Pressures in Humans–Role of Delivery Site and Sex

  2022cites this paper
• An olive-derived elenolic acid stimulates hormone release from L-cells and exerts potent beneficial metabolic effects in obese diabetic mice

  2022cites this paper
• Evaluation of the Association of CGM Metrics with Antihyperglycemic Drugs in Insulin-Treated Diabetics

  2021cites this paper
• SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

  2021cites this paper
• Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes

  2021cites this paper
• Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

  2021cites this paper
• Glucagon-like peptide-1 and beta cell glucose sensitivity-a glucose ramp study in mice.

  2021cites this paper
• An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus

  2021cites this paper
• The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update

  2021cites this paper
• Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia

  2021cites this paper
• How glucagon-like peptide 1 receptor agonists work

  2021cites this paper
• Anti-obesity drug discovery: advances and challenges

  2021cites this paper
• Patient initiation and maintenance of GLP-1 RAs for treatment of obesity

  2021cites this paper
• Regulation of Postabsorptive and Postprandial Glucose Metabolism by Insulin-Dependent and Insulin-Independent Mechanisms: An Integrative Approach

  2021cites this paper
• Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects

  2021cites this paper
• Pharmacological treatment of nonresponders following bariatric surgery: a narrative review of the current evidence.

  2021cites this paper
• Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration Timing on Blood Sugar Profiles

  2021cites this paper
• New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs

  2021cites this paper
• Role of Glucose-Lowering Medications in Erectile Dysfunction

  2021cites this paper
• Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment

  2021cites this paper
• GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients.

  2020cites this paper
• Incretins in obesity and diabetes

  2020cites this paper
• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

  2020cites this paper
• A free‐energy landscape for the glucagon‐like peptide 1 receptor GLP1R

  2020cites this paper
• An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective

  2020cites this paper
• Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH

  2020cites this paper
• Hypoglycaemia and its management in primary care setting

  2020cites this paper
• On Meal Effects and DPP-4 Inhibition Islet- and Incretin Hormones in Health and Type 2 Diabetes

  2020cites this paper
• A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents

  2020cites this paper
• Impaired counterregulatory responses to hypoglycaemia following oral glucose in adults with cystic fibrosis

  2020cites this paper